VolitionRx Initiates Sponsorship of Two-time Cancer Survivor to Drive Awareness for the Importance of Early Cancer Detection

NAMUR, Belgium, Oct. 31, 2014 /PRNewswire via COMTEX/ VolitionRx Limited (OTCQB: VNRX), a life sciences company focused on developing blood-based diagnostic tests, today announced that it has initiated sponsorship of Sean Swarner, the first cancer survivor to summit Mt. Everest, to raise awareness of the importance of early detection of cancer. Through this sponsorship, VolitionRx is in-part supporting Sean s next adventure of trekking to the South Pole to help demonstrate to the world that cancer is not a death sentence, that there are steps people can take to aid in the early detection of cancer, and that survivors can enjoy a high quality of life post-treatment. Sean was diagnosed with two different, unrelated and deadly forms of cancer in his teenage years, and after an incredibly poor prognosis through which he spent a year in a medically-induced coma, stunned his doctors when he survived both diseases. With only one functioning lung, Swarner became the first cancer survivor to s
http://bit.ly/107LlXI